Intellectual Property Pulse

District Court Grants Summary Judgment and Invalidates Patent in REGENXBIO v. Sarepta Litigation

LexBlog IP

JANUARY 8, 2024

On January 5, 2024, in litigation between REGENXBIO and Sarepta Therapeutics, Judge Richard Andrews of the U.S. 10,526,617 (the ’617 Patent; licensed to REGENXBIO) is invalid as being directed to ineligible subject matter. A separate, related patent lawsuit filed by REGENXBIO and Penn against Sarepta and Catalent, Inc.

Litigation

Litigation Patent Inventor Invention

Merck General Counsel Added To Biotech Company's Board

IP Law 360

JUNE 7, 2022

Food and Drug Administration, has joined the board of directors for Regenxbio Inc., the Maryland-based biotechnology company said Tuesday. Merck's general counsel, who earlier in her career worked in-house at the U.S.

District Court Grants Summary Judgment and Invalidates Patent in REGENXBIO v. Sarepta Litigation

Merck General Counsel Added To Biotech Company's Board

Stay Connected